Site-Specific Fluorescent Labeling of Antibodies and Diabodies Using SpyTag/SpyCatcher System for In Vivo Optical Imaging
Construction of antibody-based, molecular-targeted optical imaging probes requires the labeling of an antibody with a fluorophore. The most common method for doing this involves non-specifically conjugating a fluorophore to an antibody, resulting in poorly defined, heterogeneous imaging probes that often have suboptimal in vivo behavior. We tested a new strategy to site-specific label antibody-based imaging probes using the SpyCatcher/SpyTag protein ligase system.
We used the SpyCatcher/SpyTag protein ligase system to site specifically label nimotuzumab, an anti-EGFR antibody and an anti-HER3 diabody. To prevent the labeling from interfering with antigen binding, we introduced the SpyTag and SpyCatcher at the C-terminus of the antibody and diabody, respectively. Expression and binding properties of the C-terminal antibody-SpyTag and diabody-SpyCatcher fusions were similar to the antibody and diabody, indicating that the SpyTag and SpyCatcher fusions were well tolerated at this position. Site-specific labeling of the antibody and diabody was performed in two steps. First, we labeled the SpyCatcher with IRDye800CW-Maleimide and the SpyTag with IRDye800CW-NHS. Second, we conjugated the IRDye800CW-SpyCatcher and the IRDye800CW-SpyTag to the antibody or diabody, respectively. We confirmed the affinity and specificity of the IRDye800CW-labeled imaging probes using biolayer interferometry and flow cytometry. We analyzed the in vivo biodistribution and tumor accumulation of the IRDye800CW-labeled nimotuzumab and anti-HER3 diabody in nude mice bearing xenografts that express EGFR and HER3, respectively.
Expression and binding properties of the C-terminal antibody-SpyTag and diabody-SpyCatcher fusions were similar to the antibody and diabody, indicating that the SpyTag and SpyCatcher fusions were well tolerated at this position. We confirmed the affinity and specificity of the IRDye800CW-labeled imaging probes using biolayer interferometry and flow cytometry. We analyzed the in vivo biodistribution and tumor accumulation of the IRDye800CW-labeled nimotuzumab and anti-HER3 diabody in nude mice bearing xenografts that express EGFR and HER3, respectively. Site-specifically IRDye800CW-labeled imaging probes bound to their immobilized targets, cells expressing these targets, and selectively accumulated in xenografts.
These results highlight the ease and utility of using the modular SpyTag/SpyCatcher protein ligase system for site-specific fluorescent labeling of protein-based imaging probes. Imaging probes labeled in this manner will be useful for optical imaging applications such as image-guided surgery and have broad application for other imaging modalities.
Key wordsSite-specific labeling Near infrared imaging Nimotuzumab EGFR Antibody Diabody HER3 SpyTag/SpyCatcher
Non-invasive optical imaging is an emerging approach that aids clinicians in many aspects of cancer diagnosis and treatment [1, 2, 3]. Antibody-based, molecular targeted imaging (MTI) probes are being developed for optical imaging to allow visualization of disease-specific markers. One challenge in constructing MTI probes is conjugating fluorophores to antibodies. Fluorophores are most commonly conjugated to antibodies in a non-specific manner, which can result in decreased antigen-binding affinity and poor pharmacological properties [4, 5, 6, 7]. To overcome this problem, methods have been developed to label antibodies at specific locations. Site-specific conjugation can be achieved by labeling cysteines or by incorporating peptide tags or modified amino acids [6, 7, 8, 9, 10, 11, 12, 13, 14]. While promising, each of these methodologies has limitations. For example, labeling of cysteines requires the reduction of natural disulfide bonds or the introduction of cysteine resides via genetic engineering; processes that require significant optimization [6, 7]. Peptide tags fused to biologic imaging probes can be used for site-specific modifications; however, they often have low labeling efficiencies, require expensive reagents, or result in large fluorophore-protein probes. Peptide tag-based labeling allows the fluorophore to be attached at a specific location on the imaging probe, with minimal off-site labeling [6, 7]. Examples of peptide tag-based labeling methods include SNAP/CLIP (O6-alkylguanine-DNA alkyltransferase) [8, 9], Halo-tag , Sfp phosphopantetheinyl transferase (CoA) , Sortase A , and Avi biotin ligase recognition peptide . The fusion of peptide tags increases the size (18–33 kDa) of the imaging probe and can sterically hinder antigen binding . However, site-specific labeling using peptide tags results in MTI probes that are more homogenous  compared to random approaches .
We tested the effectiveness of using the SpyCatcher/SpyTag protein ligase system to site specifically label MTI probes for in vivo optical imaging. This system is based on the collagen adhesin domain (CnaB2) of the fibronectin binding protein (FbaB) from S. pyogenes. CnaB2 contains an intramolecular isopeptide covalent bond formed between aspartate and lysine. CnaB2 is split into two fragments to produce a SpyTag (13 amino acids) and SpyCatcher (138 amino acids), which can interact and form the isopeptide bond [15, 16]. The SpyTag and SpyCatcher can be fused to either the C- or N-termini of proteins [15, 16, 17]. SpyTag and SpyCatcher protein fusions can form a conjugated product under a variety of conditions [15, 16]. This system has been used to construct antibody-like proteins , develop VLP-vaccines , construct a synthetic vaccine , conjugate a dye to an antibody , target gene delivery , and label membrane proteins .
We tested the ability of the SpyTag/SpyCatcher system to site specifically label two different-sized antibody-based MTI probes in two orientations. We constructed a C-terminus antibody-SpyTag fusion and ligated it to a fluorophore-labeled SpyCatcher. We labeled a diabody in the reverse orientation by constructing a C-terminus diabody-SpyCatcher fusion and ligated it to a fluorophore-labeled SpyTag.
We used the SpyCatcher/SpyTag system to site specifically label the anti-human epidermal growth factor receptor (EGFR) antibody, nimotuzumab, and the anti-human epidermal growth factor receptor 3 (HER3) diabody to evaluate their potential as probes for in vivo optical imaging. Overexpression of EGFR in tumors correlates with increased metastasis, decreased survival, and poor prognosis . Nimotuzumab has recently been shown to be promising probe for MTI . HER3 plays an integral role in HER2-amplified breast cancer through its ability to dimerize with HER2, contributing to tumorigenesis and correlating with poorer clinical outcomes  and trastuzumab resistance .
We demonstrated site-specific labeling of nimotuzumab and an anti-HER3 diabody using the SpyCatcher/SpyTag system for in vivo cancer imaging. We generated nimotuzumab-SpyTag and anti-HER3 diabody-SpyCatcher fusions and ligated them to fluorescently labeled SpyCatcher and SpyTag, respectively. We confirmed the ligation efficiency and in vitro binding affinity and specificity of the fluorescent-labeled nimotuzumab and anti-HER diabody. We analyzed the in vivo biodistribution and tumor accumulation properties of these EGFR and HER3 fluorescent imaging probes in mice bearing tumor xenografts expressing EGFR or HER3.
Materials and Methods
Expression plasmids were cloned using standard PCR methods and Gibson assembly . To generate pFUSEss-CHIg-Nimotuzumab-hG1-SpyTag and pFUSEss-CHIg-MBP-hG1-SpyTag plasmids, we first introduced SpyTag into the pFUSEss-CHIg-hG1 plasmid (Invivogen) at the C-terminus of the Fc domain to generate pFUSEss-CHIg-hG1-SpyTag plasmid. Nimotuzumab and anti-MBP VH domains were then introduced at the N-terminus of CH1 of the pFUSEss-CHIg-hG1-SpyTag plasmid to generate pFUSEss-CHIg-Nimotuzumab-hG1-SpyTag (see Electronic Supplementary Material (ESM): SEQ:01) and pFUSEss-CHIg-Anti-MBP-hG1-SpyTag (see ESM SEQ:02) plasmids, respectively. To generate pFUSEss-CLIg-Nimotuzumab-hG1 and pFUSEss-CLIg-Anti-MBP-hG1 plasmids, nimotuzumab and anti-MBP VL domain were introduced at the N-terminus of CL of pFUSEss-CLIg-hG1-hk plasmid (Invivogen), respectively.
We used the previously reported pCW-SpyCatcher-His6  to clone the anti-HER3-diabody and anti-MBP-diabody. To generate pCW-anti-HER3-diabody-SpyCatcher-His6 (see ESM SEQ:03) and pCW-anti-MBP-diabody-SpyCatcher-His6 (see ESM SEQ:04) plasmids, the anti-HER3-diabody and anti-MBP-diabody were PCR amplified from pCW-anti-HER3-Fab and pCW-anti-MBP-Fab plasmids , respectively, using overlap extension primers TGS157 and KA3R primers . The PCR product was cloned into Sac1/Xho1-digested pCW-SpyCatcher-His6 plasmid using Gibson assembly.
Expression and Purification of Antibodies
Nimotuzumab-SpyTag and anti-MBP-SpyTag were expressed using the Gibco™ Expi293™ Expression System (Life Technologies, catalog number A14635), according to the manufacturer’s protocol. Briefly, 1 day before transfection, Expi293F cells were diluted to 2 × 106 cells/ml in Expi293 Expression Medium (Life Technologies). On the day of transfection, 30 μg of plasmid DNA (1:1 ratio) was complexed with 80 μL ExpiFectamine™ 293 reagent. The complexed DNA was then transferred to 7.5 × 107 cells (final cell density of 2.5 × 106 cells/ml). The next day, enhancers 1 and 2 were added to the media to bring the final volume up to 30 ml. Cells were cultured for 6–7 days. Cells were spun down, and supernatant was collected and filtered through a 0.45-μm-membrane filter (Minisart, Sartorius Stedim). Protein A binding buffer (Sodium Phosphate 20 mM, 0.15 M NaCl, pH 7.2) was added to the supernatant, and the antibody-SpyTag was purified by GE Healthcare AKTA FPLC system using HiTrap MabSelect column (GE healthcare). The antibody-SpyTag was eluted using IgG elution buffer (Fisher Scientific) and neutralized with Neutralization Buffer (1 M Tris-HCl pH 9.0). Antibody-SpyTag was dialyzed overnight with phosphate-buffered saline (PBS) and concentrated using a 30 K MWCO filter (Millipore). Fragments were filter sterilized and stored at − 80 °C.
Expression and Purification of Diabody-SpyCatcher Fusions
Anti-HER3 diabody-SpyCatcher and anti-MBP diabody-SpyCatcher expression plasmids have a pelB sequence for mediating its secretion into the periplasmic space of E. coli. Plasmids were electroporated into RosettaTM (DE3) competent E. coli cells (Novagen) and cultured on LB agar plates containing carbenicillian (100 μg/m) and chloramphenicol (34 μg/ml). Single colonies were picked and cultured overnight in Instant TB media (Novagen) for 20 h at 30 °C with shaking (250 RPM). Diabody-SpyCatcher fusions were purified with the AKTA FPLC system (GE Healthcare) using HiTrap Protein L column (GE healthcare) as described previously . Briefly, the cell pellet was collected by centrifugation and re-suspended in Protein L binding buffer (sodium phosphate 20 mM, 0.15 M NaCl, pH 8.0). The cell pellet was lysed using a Cell Disruptor (Constant System LTD. USA) set at 35 Kpsi. The cell lysis solution was centrifuged at 12,000×g for 20 min. The supernatant was collected and filtered through a 0.45-μm-membrane filter (Minisart, Sartorius Stedim) and loaded onto a HiTrap Protein L column using Akta Prime system (GE Healthcare). Diabodies were eluted using IgG elution buffer (Fisher Scientific) and neutralized with neutralization buffer (1 M Tris-HCl pH 9.0). Purified diabodies were dialyzed overnight in PBS and concentrated using 10 K MWCO filter. Diabodies were filter sterilized and stored at − 80 °C.
IRDye800CW Labeling of SpyTag and SpyCatcher
The SpyTag peptide (AHIVMVDAYKPTK) was purchased from Genescript. IRDye800CW-NHS ester (LI-COR Biosciences Co., Lincoln, NE) was used to label the SpyTag. 1 mg of SpyTag in 1 ml phosphate-buffered saline (PBS, pH 7.4) was labeled with 3-fold molar excess of IRDye800CW–NHS by slowly rotating the mixture for 2 h at room temperature protected from light followed by rotating overnight at 4 °C. The reaction was quenched with molar excess of 1 M Tris. The labeled SpyTag was stored at − 20 °C.
The SpyCatcher with a cysteine at the N-terminus was purchased from Kerafast (#EOX004). IRDye800CW-Maleimide (LI-COR Biosciences Co., Lincoln, NE, USA) and used to label the cysteine-SpyCatcher. SpyCatcher (1 mg) in 1 ml phosphate-buffered saline (PBS, pH 7.4) was reduced by adding 70-fold molar excess of Tris(2-Carboxyethyl)Phosphine hydrochloride (TCEP) and incubated overnight at 4 °C with shaking. Excess TCEP was removed using Zeba Spin Desalting Columns, 7 K MWCO (Thermo Scientific, catalog number 89892). The reduced SpyCatcher was labeled with 10-fold molar excess of IRDye800CW–Maleimide by rotating for 2 h at room temperature protected from light followed by rotating overnight at 4 °C. Excess dye was removed by passing the solution through 5 ml Zeba Spin Desalting Columns, 7 K MWCO. The labeled SpyCatcher was stored at − 80 °C.
Ligation of Antibody-SpyTag with SpyCatcher-IRDye800CW and Diabody-Catcher with SpyTag-IRDye800CW
Nimotuzumab-SpyTag and anti-MBP-SpyTag (10 μM) were ligated to SpyCatcher-IRDye800CW (30 μM) for 3 h at room temperature in the presence of phosphate-citrate buffer, pH 7, as described by Alam et al.  and Zakeri et al. . Ligated products were named to reflect orientation the orientation of the SpyTag and SpyCatcher. For example, antibody-SpyCatcher reacted with SpyTag-IRDye800CW was labeled antibody-SpyCatcher/SpyTag-IRDy800CW. Nimotuzumab-SpyTag/ SpyCatcher-IRDye800CW and anti-MBP-SpyTag/SpyCatcher -IRDye800CW were purified using Protein A chromatography to remove unligated SpyCatcher-IRDye800CW. Anti-HER3 diabody-SpyCatcher and anti-MBP diabody-SpyCatcher (10 μM) were ligated to SpyTag-IRDye800CW (30 μM) using the same protocol described previously . Diabody-SpyCatcher/SpyTag-IRDye800CW products were filtered through 10 kDa MWCO concentrator (Millipore). The filtration was repeated four times with PBS to remove unligated SpyTag-IRDye800CW.
Antibody-SpyTag/SpyCatcher-IRDye800CW and diabody-SpyCatcher/SpyTag-IRDye800CW were filter sterilized using Millipore Ultrafree MC Centrifugal Filter Device. The concentration was measured using the formula: Protein Conc (mg/ml) = (A280-(0.030A780))/εProtein × MWprotein × dilution factor. 0.03 is a correction factor for the absorbance of the IRDye800CW at 280 nm (equal to 3.0% of its absorbance at 780 nm). εProtein is the molar extinction coefficient for protein. MWprotein is the molecular weight of the protein. Dilution factor is the dilution of the labeled protein prior to measurement by spectrophotometer. The number of IRDye800CW molecules on the antibody or diabody was calculated using the following formula: IRDye800CW/protein = (A789/εIR)/(A280 – (0.03 × A778)/εProtein), where ɛIR is the molar extinction coefficient of IRDye800CW and ɛProtein is the molar extinction coefficients of the antibody or diabody.
Purified IRDye800CW labeled and unlabeled antibodies and diabodies were resolved under reducing or non-reducing conditions using a precast BioRad 4–15 % gel (BioRad, catalog number 56–1084) with a BioRad PowerPac™ Cell. Gels were stained with coomassie blue. After destaining, protein bands were visualized by BioRad GelDoc XR+ system. Unstained SDS-PAGE gels were scanned using the Odyssey Infrared Imaging system (LI-COR Bioscience) and images processed using the Odyssey 3.0.16 application software (LI-COR Bioscience).
Electrophoresis-Based Analysis on Agilent 2100 Bioanalyzer
The molecular weight (MW) and purity of antibodies and diabodies were measured using High Sensitivity Protein 250 Kit (Agilent, catalog number 5067–1575), according to the manufacturer’s protocol. Briefly, antibodies and diabodies (1 mg/ml) were labeled with fluorescent dye and analyzed using the 2100 Bioanalyzer System (Agilent). The molecular weight and peak areas were calculated using 2100 Expert software (Agilent).
Kinetic analyses were performed using a ForteBio OctetRed 384 instrument, according to the manufacturer’s protocols. SpyCatcher/SpyTag Nimotuzumab constructs were immobilized to anti-human IgG Fc-capture sensors (ForteBio) and its interaction with the recombinant hEGFR (R&D system) analyte was measured. For the SpyCatcher/SpyTag anti-HER3 diabody, recombinant Fc-hHER3 (R&D system) was immobilized to anti-human IgG Fc-capture sensors (ForteBio), and its interaction with the diabody analyte was measured. The unlabeled anti-HER3 diabody was immobilized to amine-reactive generation 2 (ARG2) sensors (ForteBio), and its interaction with the recombinant Fc-hHER3 (R&D system) analyte was measured. Antibodies and fragments were immobilized to sensors by dipping the sensor in a 384-well tilted-bottom plate, containing 50 μl of 10–12 μg/ml of antibody or fragment. Association rates (kon) were monitored for 2–5 min, and dissociation rates (koff) were monitored for 10 min. Binding reactions were performed at 30 °C in PBS. Data was collected with Octet Data Acquisition version 8.1 (ForteBio) and globally fit to 1:1 binding model using Octet Data Analysis version 7.1 (ForteBio).
The human squamous carcinoma A431 cell line over-expressing EGFR was obtained from ATCC (Rockville, MD, USA). The human head and neck squamous cell carcinoma FaDu cell line over-expressing HER3 was obtained from ATCC (Rockville, MD, USA). Cells were propagated by serial passage in RPMI and MEM/EBSS medium, respectively, supplemented with 10 % fetal bovine serum (Biochrom) at 37 °C in a humidified atmosphere of 5 % CO2.
Binding of antibody-SpyTag/SpyCatcher-IRDye800CW to A431 cells and diabody-SpyCatcher/SpyTag-IRDye800CW to FaDu cells were determined using flow cytometry. For flow cytometric analysis, 2 × 105 cells/tube were incubated with 50 pmoles of IRDye800CW labeled antibodies or diabodies at room temperature, protected from light, for 60 min, followed by three washes with PBS, pH 7.4. Fluorescent emission of cells was monitored using a Gallios flow cytometer (Beckman Coulter, Inc.) at 640 nm excitation with emission filter set up at 745–825 nm. Flow cytometry data were analyzed using Kaluza (Beckman Coulter, Inc.).
In Vivo Animal Imaging
Animals used in the imaging experiments were cared for and maintained under the supervision and guidelines of the University of Saskatchewan Animal Care Committee. Female CD-1 nude mice were obtained from Charles River Canada (St-Constant, Quebec, Canada) at 4 weeks of age and housed in a 12 h light/dark cycle in a temperature and humidity controlled vivarium. Animals had ad libitum access to mouse diet (Lab Diet, St. Louis, MO, USA) and water. After 1 week of acclimatization, mice were subcutaneously injected with a suspension of 1 × 107 A431 cells or FaDu cells in 100 μl of a 1:1 mixture of serum-free MEM/EBSS medium (HyClone Laboratories, Logan, UT, USA) and Matrigel matrix basement membrane (Discovery Laboware, Inc. Bedford, MA, USA) at the hind limb of each mouse. Tumor growth was followed with external caliper measurements. Tumor volume was calculated using the following formula: tumor volume = length × width2 × 0.5 . Tail vein injections of 0.5 nmole of antibody-SpyTag/SpyCatcher-IRDye800CW for A431 xenografts and diabody-SpyCatcher/SpyTag-IRDye800CW for FaDu xenografts were injected intravenously when xenografts measured 150–300 mm3. Mice were anesthetized with 2.5 % isoflurane and imaged at different time points using the Pearl Impulse Imager (LI-COR) with excitation/emission settings of 785/820 nm. The fluorescence signal was overlaid with the white light image captured by a CCD camera, and images were analyzed using Image Studio Software (version 3.1). Regions of interest (ROI) for xenografts, liver, kidneys, and background were selected from equivalent-sized areas containing the same number of pixels. Three ROIs were quantified per organ for each mouse and three mice were imaged per antibody or diabody. Antibody and diabody raised against MBP served as non-specific control in imaging experiments.
Purification and Analysis of Nimotuzumab-SpyTag Fusion
To minimize the effect of the fusion protein on antigen binding, we genetically fused the SpyTag and SpyCatcher to the heavy chain C-terminus of nimotuzumab. Expression yields of nimotuzumab-SpyTag were 5 ± 2 mg/L from Expi293F cells in culture, whereas yields of nimotuzumab-SpyCatcher were 1.0 ± 0.3 mg/L. Based on the higher expression levels of nimotuzumab-SpyTag, we used this fusion for ligation experiments. We also expressed and purified an anti-MBP antibody  as a SpyTag fusion (anti-MBP-SpyTag) for use as a control in imaging experiments.
Binding affinity of nimotuzumab IgG and anti-HER3 diabody fragments against recombinant EGFR and HER3 receptors respectively as measured by biolayer interferometry. Values presented as value ± SD
kon (M−1 s−1)
5.31E + 04 ± 1.00E + 03
9.38E-04 ± 1.12E-05
1.77E-08 ± 3.95E-10
7.82E + 04 ± 7.35E + 02
1.82E-03 ± 6.71E-06
2.32E-08 ± 2.35E-10
2.17E + 04 ± 2.19E + 02
5.28E-04 ± 8.59E-06
2.43E-08 ± 4.65E-10
1.82E + 04 ± 1.65 + 02
4.41E-04 ± 1.14E-05
2.42E-08 ± 6.6E-10
2.50E + 05 ± 3.72E + 02
8.65E-04 ± 1.91E-05
3.46E-08 ± 9.21E-10
Site-Specific Labeling of Nimotuzumab-SpyTag with IRDye800CW-SpyCatcher
After labeling quality control; molecular weight, purity, and labeling efficiencies of IgG conjugates and antibody fragments. As observed by running on Agilent 2100 Bioanalyzer system under non-reducing (IgG) and reducing (diabody) conditions using the Agilent Protein 250 kit
MW calc (kDa)
MW obs (kDa)
Near Infrared Fluorescent Imaging of Nimotuzumab-SpyTag/SpyCatcher-IRDye800CW
Purification and Analysis of Diabody-SpyCatcher Fusion
Site-Specific Labeling of Diabody-SpyCatcher Using the IRDye800CW-SpyTag
We labeled anti-HER3 and anti-MBP diabody-SpyCatchers with fluorescent SpyTag using the scheme in Fig. 3b. We labeled the SpyTag peptide (AHIVMVDAYKPTK), which has two free lysines, with IRDye800CW-NHS (Fig. 3b). The SpyTag was labeled with 3-fold molar excess of IRDye800CW–NHS in PBS, pH 7.4. We observed strong fluorescence for the SpyTag-IRDye800CW and a low level of coomassie blue staining on SDS-PAGE (Fig. 3c). We ligated the IRDye800CW-SpyTag with diabody-SpyCatcher (Fig. 3b) at a molar ratio of 3:1. The SpyTag-IRDye800CW labeled diabody-SpyCatcher conjugates were fluorescent on an SDS-PAGE (Fig. 3c). We calculated the number of IRDye800CW molecules per labeled anti-HER3 and anti-MBP diabody-SpyCatchers to be 2.76 and 2.44, respectively (Table 2). The diabody-SpyCatcher labeling was higher than the antibody-SpyTag labeling, likely due to the presence of two lysines on the SpyTag. The MW of the anti-HER3 SpyCatcher/SpyTag-IRDye800CW and the anti-MBP SpyCatcher/SpyTag-IRDye800CW diabodies were ~ 45 kDa (Fig. 3c, Table 2). The purity of the anti-HER3-SpyCatcher/SpyTag-IRDye800CW and the anti-MBP-SpyCatcher/SpyTag-IRDye800CW diabodies were 87 and 76 %, respectively (Fig. 3d, Table 2). The KD of the anti-HER3-SpyCatcher/SpyTag-IRDye800CW diabody was slightly lower (< 2-fold) then the anti-HER3-SpyCatcher (Table 1). The anti-HER3-SpyCatcher/SpyTag-IRDye800CW bound HER3-positive cell line, FaDu (Fig. 3e).
Near Infrared Fluorescent Imaging of Anti-HER3 Diabody-SpyTag/SpyCatcher-IRDye800CW
Medium-sized fragments (100 kDa) such as anti-CD105 F(ab’)2 have been shown to clear through both renal and hepatic pathways . Since we have increased the diabody size from 50 kDa to roughly 90 kDa through the addition of a SpyTag/SpyCatcher, we expected a similar clearance profile. There was a high fluorescence signal detected in both kidneys and liver injected with either the anti-HER3 or anti-MBP diabody-SpyCatcher/SpyTag-IRDye800CW that steadily decreased (Fig. 4).
Biodistribution of IRDye800CW-Labeled SpyTag and SpyCatcher
Previously, it has been shown that site-specifically labeled immunoconjugates exhibit superior in vivo behavior compared to non-specifically labeled antibodies . The SpyTag/SpyCatcher system is a robust and simple method for site-specific labeling antibodies or antibody fragments. The most common method for labeling antibodies involves the non-specific coupling of amine-reactive bifunctional probes to the primary amine on lysines, resulting in a heterogeneous probe with suboptimal pharmacological properties. We showed that antibodies and antibody fragments could be site-specifically labeled using the SpyTag/SpyCatcher system without compromising antigen affinity. Nimotuzumab and the anti-HER3 diabody have lysines in their complementarity determining regions (CDRs) and decreases in affinity have been observed with antibodies containing lysines in their CDRs that are non-specifically labeled with IRDye800CW-NHS , highlighting the advantage of labeling these types of antibodies with site-specific methods.
Although the SpyTag/SpyCatcher system relies on genetic manipulation and protein production, the irreversible covalent interaction between SpyTag and SpyCatcher fused proteins is highly specific and modular [17, 18, 19, 20, 21, 22], which makes it useful for synthesizing multiple probes for in vivo imaging. This SpyTag or SpyCatcher can be fused to either terminus of an antibody or an antibody fragment, which can then be produced in bulk and can be labeled with any desired reporter, making it useful when repeated use of large amounts of antibodies are required . The SpyTag/SpyCatcher system is smaller than the commonly used peptide-based labeling systems such as SNAP-tag (181 a.a), CLIP-tag (181 a.a), and Halo-tag (220 a.a), and these labeling methods rely on synthetic probes for antibody labeling. A common method to site-specifically label diabodies involves adding a C-terminal cysteine. This cysteine is used to conjugate reporters with a reactive multimode [38, 39]. The SpyTag/SpyCatcher system does not require reducing agents during the labeling reaction as in case of cysteine-maleimide conjugation. Thus, disulfide bonds present in the antibodies remain oxidized during labeling, and the need for removing the reducing agent post-conjugation is eliminated . Additionally, the SpyCatcher/SpyTag reaction takes place at room temperature in the same buffer in which the antibody was purified, and there was no need to change buffers or pH. Labeling the SpyTag or SpyCatcher prior to conjugation allows repetitive labeling of different batches of antibody or different antibodies with the same batch of labeled SpyTag or SpyCatcher. The SpyTag/SpyCatcher can be placed at any site within the antibody [17, 41] without compromising expression yield and binding properties. In addition, this system provides control over the labeling ratio of antibodies and fragments by either modulating the labeling ratio of the SpyTag or SpyCatcher or by “doping” in unlabeled SpyTag or SpyCatcher into the ligation reaction.
The addition of the SpyCatcher, a 15 kDa protein, to an antibody may result in an immune response. Full-length SpyCatcher has been shown to elicit an immune response in mice . To reduce this, Li et al.  developed an N-terminal-truncated SpyCatcher that dramatically reduces the immune response . Further, the amount of antibody required for molecular imaging is generally far lower than that of therapeutic requirements  reducing the chance for an immunogenic reaction. Fierer et al.  and Siegmund et al.  engineered the SpyTag/SpyCatcher system to ligate two peptides, SpyTag, and Ktag using a SpyLigase enzyme. This system provides another avenue to eliminate the immune response as the SpyCatcher is removed from the ligated product. The SpyLigase system has been used to label antibodies with drug conjugates . The ligation efficiency of the SpyLigase system is significantly lower than that of SpyTag/SpyCatcher system.
In conclusion, the SpyTag/SpyCatcher protein ligase provides a simple robust ligation system for labeling antibodies and antibody fragments. The modular nature of this approach allows rapid labeling of multiple batches of antibodies or many different antibodies. This system will be useful for rapidly evaluating imaging probes in murine models of disease. In addition to optical probes, the SpyTag/SpyCatcher systems should also have applications with other imaging modalities and in constructing antibody drug conjugates.
We thank the members of the Dr. Geyer and the Dr. Fonge Laboratories for critical review of this manuscript and sharing their experiences. We thank Carolina Gonzalez for technical contributions.
MKA designed and performed the experiments and analyzed the data. AE designed and performed the experiments and analyzed the data. KB designed and supervised the experiments, and analyzed the data. WB performed the experiments. MKA and AE wrote the manuscript. KB reviewed and edited the manuscript. HF edited the manuscript and supervised the study. CRG supervised the study and wrote and edited the manuscript.
Canadian Cancer Society Research Institute Innovation Grant 705323, Western Diversification Canada 12939.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 12.Massa S, Vikani N, Betti C, Ballet S, Vanderhaegen S, Steyaert J, Descamps B, Vanhove C, Bunschoten A, van Leeuwen FWB, Hernot S, Caveliers V, Lahoutte T, Muyldermans S, Xavier C, Devoogdt N (2016) Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: a versatile strategy for multiple molecular imaging modalities. Contrast Media Mol Imaging 11:328–339CrossRefPubMedGoogle Scholar
- 24.Chekol R, Bernhard W, Viswas RS et al (2017) 89Zr-nimotuzumab for potential clinical translation as an anti-EGFR immunoPET agent. J Nucl Med 58:688Google Scholar
- 29.Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SA (2013) An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 73:6024–6035CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Voss SD, Smith SV, DiBartolo N, McIntosh LJ, Cyr EM, Bonab AA, Dearling JLJ, Carter EA, Fischman AJ, Treves ST, Gillies SD, Sargeson AM, Huston JS, Packard AB (2007) Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A 104:17489–17493CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Olafsen T, Cheung CW, Yazaki PJ, Li L, Sundaresan G, Gambhir SS, Sherman MA, Williams LE, Shively JE, Raubitschek AA, Wu AM (2004) Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel 17:21–27CrossRefPubMedPubMedCentralGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.